Vascular Origins of Alzheimer's Disease Gain Ground as Amyloid Hypothesis Faces Mounting Challenges
核心洞察
Growing evidence points to the cerebral vascular system, rather than amyloid plaques alone, as a key driver in the development of Alzheimer's disease (搜索).
Plaques are found in cognitively healthy individuals, and anti-amyloid drugs like lecanemab and aducanumab have not slowed cognitive decline beyond older treatments.
A comprehensive dementia (搜索) literature review found modifiable risk factors, many tied to vascular health, could account for up to 45 percent of dementia cases.
Alzheimer's disease (搜索), the most common form of dementia (搜索), may not originate primarily from the buildup of toxic proteins in the brain, according to a growing body of evidence that points instead to the bloodstream and the cerebral vascular system. The reappraisal, described in a review published by The Conversation and republished by Nautilus, challenges the long-dominant amyloid hypothesis that has guided most pharmaceutical research in the field.
For years, drug development in Alzheimer's disease (搜索) has centered on the amyloid hypothesis, which holds that accumulation of beta-amyloid (搜索) protein in the brain, in the form of plaques, is the primary cause of dementia (搜索). Under normal conditions, beta-amyloid is cleared by the blood and lymphatic systems or eliminated within the brain by protective cells such as microglia and astrocytes, along with enzymes. When these cleanup mechanisms malfunction while beta-amyloid production continues, plaques form, and prolonged exposure over decades is thought to damage neurons and cause memory loss.
Two Findings That Undermine the Amyloid Hypothesis
The review cites two major discoveries that have called this model into question. First, significant accumulations of plaques have been found in individuals with no cognitive impairment, and amyloid is a protein that can be produced naturally in response to viral infection or inflammation. Second, newly developed drugs such as lecanemab and aducanumab, designed to directly break down plaques, have shown that even when amyloid is almost completely eliminated, cognitive decline continues at a similar rate to that seen with older treatments — which have the advantage of being less expensive and better tolerated.
Those observations suggest that amyloid plaques may not be the source of the problem but rather the consequence of an underlying abnormality. The review frames the issue through a mechanical metaphor: relentlessly scrubbing rust off a car does not address what causes the rust, and once the damage is done, the vehicle's lifespan is permanently altered. The implication for drug development is a shift toward prevention and early detection of the first signs of wear and tear, which is where biomarkers — biological indicators that can identify disease before symptoms appear — come into play.
The Case for the Cerebral Vascular System
Attention has increasingly turned to the brain's vascular system, which supplies neurons with oxygen and nutrients. A hypothesis that has emerged over the past decade proposes that conditions such as vascular diseases, hypertension (搜索) and type 2 diabetes (搜索) damage blood vessels and create areas of inflammation. Beyond restricting blood flow to the brain, that inflammation is thought to cause the accumulation of beta-amyloid (搜索), ultimately leading to neuron death.
Several findings support this model. Vascular abnormalities — including changes in blood flow dynamics, specifically a decrease in blood flow and blood volume, as well as the presence of hemorrhages — are now recognized as early signs of Alzheimer's disease (搜索). In addition, one of the most comprehensive reviews of the literature on dementia (搜索) found that certain risk factors could account for up to 45 percent of dementia cases, with a significant proportion of those risks directly linked to vascular health. Among the factors identified are high levels of LDL cholesterol, physical inactivity, type 2 diabetes (搜索), smoking, high blood pressure, excessive alcohol consumption and obesity.
The review notes that addressing these factors offers concrete avenues for preventing or treating these conditions throughout life, thereby reducing the burden on the brain. The central challenge remaining is to precisely characterize the vascular system at an early stage — potentially decades before diagnosis — to identify the changes that lead to disease. While the relationship between the vascular system and dementia (搜索) is being studied in greater depth, the review states there is a significant lack of precise data on the subject.
Moving Beyond Amyloid Toward a Multi-Factorial Model
Research is increasingly examining non-amyloid factors that may be responsible for the disease. The tau protein (搜索) appears to play an important role, and other mechanisms are drawing scientific interest, including the role of the immune system, mitochondrial dysfunction and communication problems between neurons. A growing number of scientists are proposing a multi-factorial approach in which the various aspects of the disease interact with one another rather than acting in isolation.
New vascular biomarkers support the idea that damage to the brain's blood-brain barrier (搜索) is linked to Alzheimer's disease (搜索). The discovery that certain cells from the blood system infiltrate the central nervous system — a sign that the vascular "plumbing" is leaking — is correlated with cognitive decline and the presence of amyloid plaques. Improvements in imaging techniques and the advent of artificial intelligence in biomedical research are also enabling assessment of brain health much faster and with greater sensitivity than was previously possible.
Until new therapeutic approaches are developed, the review emphasizes that the best way to protect the brain is to focus on controllable factors — staying physically and socially active throughout life.